SEC Focusing On Drug Makers; Full Disclosure Of Tests Called Key

The Securities and Exchange Commission is scrutinizing biotechnology companies as part of a wider effort to ensure that companies don't mislead investors by covering up negative results of clinical trials. The SEC's Boston office has made the biotech industry a new focus because of the concentration of companies in the area and the possibility that selective disclosure could seriously harm investors, say lawyers and company officials.

Back to news